Results 1 to 10 of about 21,016 (175)

Acquisition of Daptomycin Resistance by Enterococcus faecium Confers Collateral Sensitivity to Glycopeptides

Frontiers in Microbiology, 2022
Daptomycin is a last-line antibiotic used in the treatment of multidrug-resistant Enterococcus faecium infections. Alarmingly, daptomycin-resistant E. faecium isolates have emerged.
Changrui Qian, Tieli Zhou
exaly   +3 more sources

Enhanced Antibacterial Properties of Lyotropic Liquid Crystalline Nanoparticles via Curvature Modulation [PDF]

Advanced Science, Volume 13, Issue 55, 5 October 2026.
Lipid nanostructured particles with increasing negative Gaussian curvature progress from vesicles to P‐cubosomes and D‐cubosomes. This curvature hierarchy enhances interaction with bacterial membranes, promotes membrane remodeling and leakage, and potentiates daptomycin activity against MRSA.
Xiangfeng Lai, Shuhong Wang, Chenguang Ding, Xenia Kostoulias, Anton P. Le Brun, Hsien‐Yi Hsu, Jhih‐Hang Jiang, Yajun Wang, Richard A. Strugnell, Anton Y. Peleg, Hsin‐Hui Shen   +10 more
wiley   +2 more sources

The Combination of Daptomycin with Fosfomycin is More Effective than Daptomycin Alone in Reducing Mortality of Vancomycin-Resistant Enterococcal Bloodstream Infections: A Retrospective, Comparative Cohort Study

Infectious Diseases and Therapy, 2023
Introduction High-dose daptomycin-based combinations are recommended for vancomycin-resistant Enterococcus (VRE) bloodstream infection (BSI). Preclinical data have shown a synergistic effect of daptomycin/fosfomycin combinations against VRE.
Chang Shan-chwen, Jann-Tay Wang, Yee-Chun Chen   +2 more
exaly   +2 more sources

Therapeutic drug monitoring of daptomycin in a critically ill patient cohort [PDF]

Frontiers in Medicine
BackgroundPharmacokinetics of antimicrobial agents are altered in critically ill patients. Therefore, therapeutic drug monitoring (TDM) has gained much attention in recent years.
Rubi Stephani Hellwege, Mattia Müller, Rolf Erlebach, Onur Sazpinar, Alix Buhlmann, Reto A. Schuepbach, Sascha David, Sascha David, Daniel A. Hofmaenner   +8 more
doaj   +2 more sources

Removal of peptidoglycan and inhibition of active cellular processes leads to daptomycin tolerance in Enterococcus faecalis.

PLoS ONE, 2021
Daptomycin is a cyclic lipopeptide antibiotic used in the clinic for treatment of severe enterococcal infections. Recent reports indicate that daptomycin targets active cellular processes, specifically, peptidoglycan biosynthesis. Within, we examined the
Rachel D Johnston, Brittni M Woodall, Johnathan Harrison, Shawn R Campagna, Elizabeth M Fozo   +4 more
doaj   +1 more source

Daptomycin Resistance Occurs Predominantly in vanA-Type Vancomycin-Resistant Enterococcus faecium in Australasia and Is Associated With Heterogeneous and Novel Mutations

Frontiers in Microbiology, 2021
Healthcare associated infections caused by vancomycin-resistant Enterococcus faecium (VREfm) have a major impact on health outcomes. VREfm is difficult to treat because of intrinsic and acquired resistance to many clinically used antimicrobials, with ...
Lucy Li, Charlie Higgs, Adrianna M. Turner, Yi Nong, Claire L. Gorrie, Claire L. Gorrie, Norelle L. Sherry, Norelle L. Sherry, Norelle L. Sherry, Kristin H. Dyet, Torsten Seemann, Deborah A. Williamson, Deborah A. Williamson, Timothy P. Stinear, Benjamin P. Howden, Benjamin P. Howden, Benjamin P. Howden, Glen P. Carter, Glen P. Carter   +18 more
doaj   +1 more source

A Pharmacovigilance Analysis of Daptomycin Use Based on CLSI Susceptible Dose-Dependent Category

Infectious Diseases and Therapy, 2023
Introduction Daptomycin doses 8–12 mg/kg are recommended for susceptible dose-dependent Enterococcus species. However, data remain limited on safety outcomes of such dosing, compared to standard 4–6 mg/kg dosing.
Ming M. Zhang, Ryan W. Stevens, Jennifer L. Adema, Kristin C. Mara, Audrey N. Schuetz, Aaron J. Tande, Christina G. Rivera   +6 more
doaj   +1 more source

Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach. [PDF]

PLoS ONE, 2016
Our objective was to study the pharmacodynamics of daptomycin in the presence of varying concentrations of human serum (HS) in vitro to quantify the fraction of daptomycin that is 'active'.
Samira M Garonzik, Justin R Lenhard, Alan Forrest, Patricia N Holden, Jϋrgen B Bulitta, Brian T Tsuji   +5 more
doaj   +1 more source

Metabolic changes associated with adaptive resistance to daptomycin in Streptococcus mitis-oralis

BMC Microbiology, 2020
Background Viridans group streptococci of the Streptococcus mitis-oralis subgroup are important endovascular pathogens. They can rapidly develop high-level and durable non-susceptibility to daptomycin both in vitro and in vivo upon exposure to daptomycin.
Allison Parrett, Joseph M. Reed, Stewart G. Gardner, Nagendra N. Mishra, Arnold S. Bayer, Robert Powers, Greg A. Somerville   +6 more
doaj   +1 more source

Cell Membrane Adaptations Mediate β-Lactam-Induced Resensitization of Daptomycin-Resistant (DAP-R) Staphylococcus aureus In Vitro

Microorganisms, 2021
The reversal of daptomycin resistance in MRSA to a daptomycin-susceptible phenotype following prolonged passage in selected β-lactams occurs coincident with the accumulation of multiple point mutations in the mprF gene.
Nagendra N. Mishra, Arnold S. Bayer, Sarah L. Baines, Ashleigh S. Hayes, Benjamin P. Howden, Christian K. Lapitan, Cassandra Lew, Warren E. Rose   +7 more
doaj   +1 more source